conference reports

Thursday, 12 February 2009- Professor Francois Desgrandchamps (France) delivered a state-of-the-art lecture on minimally invasive therapy for BPH/LUTS at the recently concluded 18th European Urology Forum in Davos, Switzerland,...

Friday, 14 November 2008 - Nymox Pharmaceutical Corporation’s investigational benign prostatic hyperplasia (BPH) drug NX-1207 provided significant improvement in urinary symptoms for men afflicted with diseases, according to...

Monday, 27 October 2008- Researchers from the biotechnology firm Dendreon Corporation recently presented in a scientific congress held in Geneva, Switzerland, preclinical data on its lead small molecule candidate, D-3263, which...

Wednesday, 17 September 2008-  The latest clinical data on the investigational BPH (Benign Prostatic Hyperplasia) drug NX-1207 will be presented by Dr. Pat  Hezmall (Arlington, Texas) at the 87th Annual Meeting of the...

Tuesday, 6 May 2008 - Prof. Cesare Selli (Pisa, Italy) selected the highlights of abstracts on prostate diseases presented at the 23rd Annual EAU Congress in Milan, Italy from 26 to 29 March 2008. He noted that of the total 990...

Monday, 5 May 2008 - Prof. Cesare Selli (Pisa, Italy) selected the highlights of abstracts on prostate diseases presented at the 23rd Annual EAU Congress in Milan, Italy from 26 to 29 March 2008. He noted that of the total 990...

Friday, 28 March 2008 - The pathophysiologic links between lower urinary tract symptoms (LUTS) and erectile dysfunction (ED) can potentially impact the way physicians diagnose and treat urologic disorders. This was one of the...

CombAT stands for the combination of Avodart® and Tamsulosin. Claus Roehrborn was the presenter of the two-year follow-up data of the CombAT study in which more than 1600 patients were randomized either to receive combination...

The presentation entitled "Profile and management of patients treated for the first time for LUTS/BPH in four European countries" by Fourcade, he analyzed the data of a survey done in four different countries. The survey...

In the presentation entitled "Alfusozin 10 mg once daily shows no deleterious effect on ejaculation components in real life practice" Fitzpatrick and Rosen evaluated the male sexual health questionnaire, a psychometrically...